K
Katherine Hastings
Researcher at Yale University
Publications - 9
Citations - 1158
Katherine Hastings is an academic researcher from Yale University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 5, co-authored 6 publications receiving 623 citations. Previous affiliations of Katherine Hastings include Yale Cancer Center.
Papers
More filters
Journal ArticleDOI
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott N. Gettinger,Jungmin Choi,Katherine Hastings,Anna Truini,Ila Datar,Ryan T. Sowell,Anna Wurtz,Weilai Dong,Guoping Cai,Mary Ann Melnick,Victor Y. Du,Joseph Schlessinger,Sarah B. Goldberg,Anne C. Chiang,Miguel F. Sanmamed,Ignacio Melero,Jackeline Agorreta,Luis M. Montuenga,Richard P. Lifton,Soldano Ferrone,Paula B. Kavathas,David L. Rimm,Susan M. Kaech,Kurt A. Schalper,Roy S. Herbst,Katerina Politi +25 more
TL;DR: CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs.
Journal ArticleDOI
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah Blythe Doroshow,Miguel F. Sanmamed,Katherine Hastings,Katerina Politi,David L. Rimm,Lieping Chen,Ignacio Melero,Kurt A. Schalper,Roy S. Herbst +8 more
TL;DR: The advances to date in utilizing PD-L1 and tumor mutational burden, as well as novel markers of tumor inflammation, to ascertain which patients are most likely to benefit from ICIs are described.
Journal ArticleDOI
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Katherine Hastings,Helena A. Yu,Helena A. Yu,Wei Wei,Francisco Sanchez-Vega,Michelle DeVeaux,Jungmin Choi,Hira Rizvi,Aaron Lisberg,A. Truini,Christine A. Lydon,Zongzhi Liu,B.S. Henick,B.S. Henick,Anna Wurtz,Guoping Cai,Andrew J. Plodkowski,Niamh Long,Darragh Halpenny,J. Killam,Isabel B. Oliva,Nikolaus Schultz,Gregory J. Riely,Gregory J. Riely,Maria E. Arcila,M. Ladanyi,Daniel Zelterman,Roy S. Herbst,Roy S. Herbst,Sarah B. Goldberg,Sarah B. Goldberg,Mark M. Awad,Edward B. Garon,Scott N. Gettinger,Scott N. Gettinger,Matthew D. Hellmann,Matthew D. Hellmann,Katerina Politi,Katerina Politi +38 more
TL;DR: Understanding the heterogeneity of EGFR mutant tumors may be informative for establishing the benefits and uses of PD-(L)1 therapies for patients with this disease.
Journal ArticleDOI
Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Giorgia Foggetti,Chuan Li,Hongchen Cai,Jessica A. Hellyer,Wen-Yang Lin,Deborah Ayeni,Katherine Hastings,Jungmin Choi,Jungmin Choi,Anna Wurtz,Laura Andrejka,Dylan Maghini,Nicholas Rashleigh,Stellar Levy,Robert J. Homer,Scott N. Gettinger,Maximilian Diehn,Heather A. Wakelee,Dmitri A. Petrov,Monte M. Winslow,Katerina Politi +20 more
TL;DR: In this paper, the effects of inactivating 10 putative tumor suppressor genes in a mouse model of EGFR-driven Trp53-deficient lung adenocarcinoma were quantified.
Posted ContentDOI
Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Giorgia Foggetti,Chuan Li,Hongchen Cai,Jessica A. Hellyer,Wen-Yang Lin,Deborah Ayeni,Katherine Hastings,Jungmin Choi,Anna Wurtz,Laura Andrejka,Dylan Maghini,Nicholas Rashleigh,Stellar Levy,Robert J. Homer,Scott N. Gettinger,Maximilian Diehn,Heather A. Wakelee,Dmitri A. Petrov,Monte M. Winslow,Katerina Politi +19 more
TL;DR: How genetic alterations can have dramatically different biological consequences depending on the oncogenic context and that the fitness landscape can shift upon drug treatment is highlighted.